Fc-Fusion Protein Technology Has Huge Potential for Drug Half-Life Extension

Recent years have seen an increase in the need for novel strategies for drug half-life extension as a result of poor drug performance in clinical trials due to their short serum half-lives that greatly reduce the progress of novel drug development. After putting a lot of effort into drug half-life extension research, many strategies to prolong drug half-life have been proven to have tremendous possibilities, especially the Fc-fusion technology, which is commonly suitable for the majority of therapeutic protein modification.

A study showed that 45 monoclonal antibodies and monoclonal antibody-derivative medicines have received therapeutic use approval in the United States over the previous few decades, of which nine of the 45 approved monoclonal antibody products are Fc-fusion proteins, which firmly established Fc-fusion proteins as the alluring half-life extension technique.

In order to help researchers have a successful drug development, global biotech companies have been working hard to improve their development technologies and platforms and are committed to providing bioactive natural protein conjugation services for drug half-life extension, in which one of the commonly utilized technologies is Fc-fusion-based half-life extension, as Creative Biolabs did.

At present, the majority of existing half-life extension drugs are achieved through Fc-fusion. One of the essential steps in the process of Fc-fusion drug half-life extension is Fc-fusion protein development, which much depends on the development platform and the skills of the technicians. Therefore, researchers must select a service provider equipped with skilled technicians and cutting-edge platforms if they want to make drug development easy and successful.

The other critical step in the process of Fc-fusion drug half-life extension is the Fc-fusion protein analysis, which, due to its complexity and diversity, can provide researchers with reliable data and analysis reports to confirm the properties of Fc-fusion proteins. The methods of Fc-fusion protein analysis ranged widely, for example, from ion-exchange chromatography to imaged capillary isoelectric focusing to confirm the primary structure, identity, and purity and integrity of the Fc-fusion proteins, which are required in the process of Fc-fusion-based drug half-life extension.

Creative Biolabs, an industry-leading half-life services provider, is committed to working hard in this field and strives to provide the best and most reliable half-life services to support researchers’ studies on drug half-life extension, especially the Fc-fusion-based drug half-life extension service. Armed with a team of scientific minds and cutting-edge technologies, this company has the confidence to better serve clients all over the world and advance target drug research.